Lilly Data Show Zepbound Reduces Type 2 Diabetes Risk Long Term

 
• By Joseph Haas

An extension of the pivotal study backing Zepbound (tirzepatide)’s approval for obesity demonstrated 94% risk reduction for type 2 diabetes as well as sustained weight loss over three years.

Preventive medicine
Lilly reports data showing a diabetes prevention benefit with tirzepatide • Source: Shutterstock

More from Clinical Trials

More from R&D